Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose-adjusted oral vitamin K antagonist (VKA) for the prevention of stroke and non-central nervous system systemic embolism in subjects with nonvalvular atrial fibrillation scheduled for cardioversion

Next Previous
Trial Profile

A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose-adjusted oral vitamin K antagonist (VKA) for the prevention of stroke and non-central nervous system systemic embolism in subjects with nonvalvular atrial fibrillation scheduled for cardioversion

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Vitamin K antagonists
  • Indications Cardiovascular disorders; Stroke; Thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms X-VeRT
  • Sponsors Bayer

    • Most Recent Events

    • 09 Oct 2021 Results of pre-planned post hoc analysis; assessing whether early cardioversion and high CHADS2 scores predicted sinus rhythm at 6 weeks from cardioversion, published in the Europace
    • 30 Aug 2017 Results from an X-VeRT substudy presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 01 Sep 2015 According to a Janssen Pharmaceuticals media release, data from this study were published in the European Heart Journal.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top